Glaxosmithkline Pakistan Limited · PSX:GLAXO
Glaxosmithkline Pakistan — Investor Presentation (May 2026)
27 slides from Glaxosmithkline Pakistan's investor presentation, May 5, 2026
Slide 1: Corporate Briefing Session 2026
CORPORATE BRIEFING SESSION 2026
Slide 2: Meeting link and Q&A via Vevox
Meeting link and Q&A via Vevox MS Team Link for https://teams.microsoft.com/meet/259457435030350?p=ANlBOTrLB8QTcZ Attendees CwYg Meeting ID: 259 457 435 030 350 Password: qb9wL7B6 Posting of Q&As via Login to https://vevox.app/#/m/130418175 Vevox Session ID: 130-418-175 Or scan the QR Code 2
Slide 3: Table of Content
TABLE OF CONTENT • Company Overview • Economic Overview • Financial Outline • Q/A 3
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by GlaxoSmithKline Pakistan Limited solely for information purposes. • This communication, except for statements of historical fact, may contain forward-looking statements that reflect current expectations, estimates, forecasts, or assumptions made by m
Slide 5: Company Overview
gsk.com Company Overview
Slide 6: Changes in Board of Directors w.e.f May 25, 2026
Changes in Board of Directors w.e.f May 25, 2026 Mr. Dmytro Oliinyk Ms. Erum Shakir Rahim Mr. Hasham Ali Baber Mr. Asad Said Jafar Mr. Muneer Kamal Dr. Naved Masoom Ali Ms. Ana Paula De (Chairperson & (Chief Executive Officer) (Chief Financial Officer) (Independent Director) (Independent Director) (
Slide 7: Our purpose: unite science, technology and talent to get ahead of disease
Our purpose We unite science, technology and talent to get ahead of disease together For health impact + shareholder returns + thriving people 05 May 2026 7
Slide 8: How we'll get Ahead Together
How we’ll get Ahead Together Our culture and thriving GSK people Ambitious We are ambitious for patients to deliver what matters better and for patients faster Accountable We are accountable for impact for impact with clear ownership and support to succeed Do the right thing We do the right thing wi
Slide 9: About the Company
About the Company GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. In Pakistan, the Company has been providing trusted quality medicines and vaccines to more than 200 million patients for over seven decades. GSK Pakistan cater
Slide 10: Economic Overview
Economic Overview CPI inflation % Monetary Policy % 28.3 22.0 22.0 22.0 22.0 22.0 20.5 23.1 19.5 19.5 20.7 17.5 17.5 15.0 17.3 13.0 12.0 12.0 12.0 12.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 10.5 11.8 12.6 11.1 9.6 6.9 6.2 7.2 6.1 4.1 5.6 4.9 5.6 4.1 3.5 3.2 3.5 2.4 1.5 0.7 0.3 Jan Feb Mar Apr May Jun J
Slide 11: Economic Overview
Economic Overview KSE – 100 (monthly average) Exchange rates (monthly average) – PKR / USD 174.1 284.4 165.5 161.6 166.7 283.8 148.6 139.4 282.4 282.0 281.7 125.6 281.3 114.3 113.3 117.8 119.7 115.1 281.0 280.9 111.3 280.7 279.4 280.5 101.4 280.1 89.0 279.3 75.9 78.4 77.9 78.5 81.1 278.6 278.7 278.7
Slide 12: Pakistan Pharma Market
Pakistan Pharma Market Value in PKR Growth Value in Rank PKR 1.1 1st (Volume) Trillion 16% Market Share Total Players CAGR 9% ~700 18% (Volume) (2025 vs 2021) Top 20 (Market Share) 6% (Value) 69% (MAT Dec 2025) 12
Slide 13: Executive Summary: Sales Rs. 66b growing by 8%
Executive Summary: Sales Rs. 66b growing by 8% YTD Dec 2025 Turnover: Rs. 66b, underlying growth of 9% vs same period last year. The impact of the price increase is partially offset by the volume slowdown. Gross profit: Rs. 24b (+58% vs SPLY); Gross Margin 37% (+12 pts vs SPLY) due to price increase
Slide 14: Statement of Profit or Loss
Statement of Profit or Loss December December • Turnover: 66 billion underlying growth of 9% versus same 2025 2024 period last year due to price increase offset by volume decrease. Amount in Rs' 000 Revenue from contracts with customers - net 65,900,901 61,187,501 • Gross profit increase due to dere
Slide 15: Balance Sheet - Assets
Balance Sheet - Assets December December 2025 2024 • Property, plant and equipment increased mainly due ASSETS Amount in Rs' 000 to addition of SKY Tower office Non-current assets • Trade receivables increase due to tender business Property, plant and equipment 14,433,368 13,262,356 Intangibles 955,
Slide 16: Balance Sheet - Liabilities
Balance Sheet - Liabilities December December 2025 2024 • Trade & other payables increase due to rise in local and EQUITY AND LIABILITIES Amount in Rs' 000 foreign creditors balances EQUITY • Taxation – provision less payment decrease due to higher Share capital 3,184,672 3,184,672 advance tax payme
Slide 17: Financial Ratios – Year to Date
Financial Ratios – Year to Date Particulars Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Return on Equity 29.8% 23.1% 2.5% 11.7% Current Ratio 2.3 2.1 1.7 1.8 Inventory Days 111 88 91 101 Trade Receivable Days 15 3 8 14 Payable Days 25 26 43 30
Slide 18: Key Financial Highlights – YTD Dec 2025
Key Financial Highlights – YTD Dec 2025 Return on Equity 30% Dividend Payout (Rs. per share) 26% 17 23% 12% 10 3% 7 6.5 2021 2022 2023 2024 2025 Profit After Tax 2020 2021 2022 2023 2024 2025 10 bn 6.5 bn 5.4 bn 2.5 bn 0.5 bn 2021 2022 2023 2024 2025 18
Slide 19: Our Award & Recognition
Our Award & Recognition TOP EMPLOYER - 2026 We are proud to announce that we have been recognised as th a Top Employer for the 6 consecutive year. This prestigious acknowledgement reflects our unwavering commitment to fostering a supportive, inclusive, and growth- oriented workplace where our employ
Slide 20: Key Brands Performance – Dec 2025
Key Brands Performance – Dec 2025 14 10 5 5 4 Billion PKR Billion PKR Billion PKR Billion PKR Billion PKR
Slide 21: Our Global Pipelines
Our Global Pipelines Specialty Care Vaccines General Medicine • Blenrep • Shingrix • Trelegy • Jemperli • Bexsero • Zejula • Bepi – Hep B Blenrep: Approved in 15 markets Jemperli & Zejula: Solid tumor footprint expansion at pace in different indications – Endometrial and Ovarian Cancer. 21
Slide 22: Environmental Sustainability
Environmental Sustainability GSK launches multi-million-pound partnership with WWF to conserve and restore freshwater resources for nature, people and business resilience Together, GSK and WWF will work to use the power of nature to boost ecosystems, biodiversity and human wellbeing in key water-str
Slide 23: Key Business Risks
Key Business Risks Risk Area Risk Description Rising Fuel Prices & Inflation The geopolitical situation led to a significant escalation in fuel costs of around 50% from December 2025 to April 2026. Concurrently, inflation increased from 5.6% in December 2025 to 10.9% in April 2026. Currency Devaluat
Slide 24: Questions & Answers
Questions & Answers @ ask.com
Slide 25: Questions Received in Advance
Questions Received in Advance Any specific reasons, why the sales revenue of Antibiotics segment was down in 2025? Or there is strategic shift to other segments like Derma and pain-killers? Do you think as the govt deregulate prices of non-essential drugs, we may see increasing shift to cheaper loca
Slide 26: Questions Received in Advance
Questions Received in Advance GLAXO launched Shingrix vaccines last year? How is the response to this product category? Where do you mainly source APIs from? Why is the promotional allowance reduced drastically from over Rs2bn in 2024 to Rs0.6bn in 2025? Any specific reason?
Slide 27: Thank You
Thank You Share your feedback
GlaxoSmithKline Pakistan — Investor Presentation (May 2026) on 6ix